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Summary 
The decision reached by the DMC in May 2018 failed in my view to demonstrate proper regard for the 
purpose and principles of the HSNO Act. The barriers that EPA relied upon to prevent the effects of in vitro 
techniques from modifying genes or other genetic material in cells or organisms are not reliable and do not 
exist in all eukaryotes that may be exposed. Furthermore, the effects on prokaryotes were not even 
considered despite the certainty of exposure when this technology is used outside of contained facilities. 
The interpretations of key terms from the HSNO Act explicitly or implicitly used by staff and the DMC were 
inconsistent with previous use by EPA or disconnected without good reasons from formal uses that are in 
relevant international agreements. Moreover, the decision was taken in a short timeframe with limited 
input from other government agencies and no input from the public or specialist scientific community. 
While that may have been EPA’s legal prerogative, as laid out in paragraph 18 (below) the decision-making 
process did not reflect the seriousness of the decision. 
External treatments of cells and organisms with dsRNA is an important research technique and valuable 
biotechnology. In time external treatments of organisms with dsRNA in the out-of-doors may prove to be 
effective, provide benefits and may be done at acceptable risks to human health and the environment. 
Regulation on a case-by-case basis will help to accomplish this. However, ensuring New Zealand the benefits 
of responsible and safe biotechnological applications is not what this EPA decision will achieve. 
 
The previous DMC erred in concluding that external treatments of eukaryotic organisms with dsRNA cannot 
cause heritable effects through modification of genes or other genetic material.1 It also erred by not 
considering whether in vitro techniques are involved. The EPA’s use of the term in vitro techniques, among 
others, in its May 2018 determination was both inconsistent with previous uses and scientifically flawed 
leading to a decision not consistent with the purpose and principles of the HSNO Act. The key terms I will 
contest are: in vitro techniques, modify/modified and genetic material. 
Inheritance 
1. As set out in document three of my submission,2 the DMC and EPA staff relied upon an incomplete 
scientific analysis to conclude that the effects of external treatments of eukaryotic cells and organisms 
with dsRNA were not heritable. The limitations of the analysis were systematically identified in the new 
information provided to EPA (Heinemann 2019). As a result, the DMC must now recognise that external 
treatments of organisms with dsRNA can have heritable effects by modifying either genes or other 
                                               
1 Current scientific literature documents treatments of eukaryotes with externally applied dsRNA that cause heritable 
changes. See submission document three of four. 
2 Published as: Heinemann, J.A. Should dsRNA treatments applied in outdoor environments be regulated? Environ Int 
2019;in press. https://www.sciencedirect.com/science/article/pii/S0160412019306038 
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genetic material and therefore in accordance with the purpose and principles of the HSNO Act external 
treatments of cells or organisms with dsRNA creates genetically modified organisms. In other words, 
heritability was an appropriate criterion but the DMC determination was incorrect. 
2. Heritability was appropriate because it is part of how the HSNO Act defines a genetically modified 
organism. As recalled by the DMC, “genetically modified organism means, unless expressly provided 
otherwise by regulations, any organism in which any of the genes or other genetic material – 
(a) have been modified by in vitro techniques; or 
(b) are inherited or otherwise derived, through any number of replications, from any genes or other 
genetic material which has been modified by in vitro techniques” (EPA 2018a). 
Satisfying either (a) or (b) is sufficient to determine that an organism is a genetically modified 
organism. If the in vitro technique, in this case treatment with dsRNA, results in modified genes or 
genetic material being passed on, that confirms that the technique is in scope of the HSNO Act 
certainly at least as per criterion (b). The definition does not require knowing the molecular biology of 
how the modified genes or genetic material are inherited.3 
3. The DMC erred in its interpretation of the kind of modification that must occur from treatments. The 
DMC statement “that sequences derived from double-stranded RNA molecules have integrated into the 
genome of a eukaryotic cell or organism or has otherwise become inheritable in progeny of eukaryotic 
cells or organisms treated with externally applied dsRNA” (paragraph 4.9 of EPA 2018a) places the 
emphasis on propagation/inheritance of the nucleotide sequence of the dsRNA molecules used in the 
treatment. However, the Act does not say that the molecules or nucleotide sequences homologous to 
dsRNA must be heritable or preserved in offspring. To require the retention and propagation of 
particular nucleotide sequences would be inconsistent with other treatments that result in creating 
genetically modified organisms. For instance, external treatments with genome editing proteins result 
in the creation of genetically modified organisms without the nucleotide sequences of the genome 
editing protein being retained in the genes of the organism.4 The editing protein only has to modify 
genes and then it may disappear. As set out in my third submission document, there are multiple ways 
that dsRNA can alter genes or other genetic material and then disappear. 
In vitro 
4. The key term from the HSNO Act that was not used in the determination by the DMC was “in vitro 
techniques” (paragraph 4.7 of EPA 2018a), and the definition of the terms “modify” and “modified” 
were not properly articulated. These terms equate the use of dsRNA treatments to other regulated 
forms of mutagenesis that do create genetically modified organisms and are not excluded by the 
regulations from being within the scope of the HSNO Act. 
5. The staff argued “that in vitro techniques are scientific techniques that occur outside a cell or organism 
in an artificial environment” (paragraph 3.10 of EPA 2018b). The courts have already ruled on a similar 
argument made by Scion in The Sustainability Council of New Zealand Trust v. The Environmental 
Protection Authority.4 In that case Scion argued that the use of site-directed nuclease proteins was an in 
vivo technique because the enzymatic activity causing the modification of genes happened inside the 
cell.5 The court rejected Scion’s argument, saying in paragraph 26: “In this case the parties [which 
                                               




5 “[Scion] said that the genes in this procedure are not modified by in vitro techniques. Rather they are modified in 
vivo (within the treated cell) by the protein” (paragraph 21 of The Sustainability Council of New Zealand Trust v. The 
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included the EPA] are agreed that organisms resulting from the use of ZFN-1 and TALEs are organisms 
in which the genes or genetic material have been modified by in vitro techniques.” In vitro techniques 
in a process that causes the modification of genes or other genetic material are not erased because 
other reactions in the series occur in vivo.  
5.1. The March 2018 staff definition of in vitro techniques is ill advised because it could potentially 
make all existing genetically modified organisms not genetically modified organisms, thereby 
undermining the purpose and principles of the HSNO Act. For example, the use of DNA molecules 
assembled using in vitro techniques to modify genes is without doubt to use in vitro techniques to 
make a genetically modified organism. Nevertheless, the modification of genes occurs later, after 
the DNA enters a cell. There the DNA modifies genes when it is integrated into or recombined with 
DNA molecules in the nucleus or organelles in vivo (Figure 1). Clearly, that the last step occurs in 
vivo does not make genetic engineering an in vivo reaction. The in vivo reactions that result in 
modification of genes or other genetic materials may differ between materials (i.e. SDNs or 
recombinant DNA) but all these methods require in vitro techniques which include those needed 
to make the active molecules and/or to cause them to penetrate the cell or organism. dsRNA is no 
exception and multiple patents have been granted for assisting dsRNA uptake into cells and 
organisms (Deikman et al. 2017; Donohue et al. 2017; Mitter et al. 2015). 
5.2. Treating cells or organisms with DNA molecules creates genetically modified organisms regardless 
of whether the treatment uses in vitro techniques inside an “artificial environment” or outside in a 
“natural environment”. If this were not the case, then the HSNO Act would not apply to any 
genetic engineering activity by virtue of it being outside. It would make all my approvals from the 
EPA for development work unnecessary if I could just transform my research organisms with 
recombinant DNA molecules while standing on the banks of the Avon River, which is technically 
not difficult for me to do. 
5.3. The High Court in its decision in The Sustainability Council of New Zealand Trust v. The 
Environmental Protection Authority ruled that treatments with site-directed nucleases such as ZFN 
or TALEN proteins create genetically modified organisms regardless of whether the mRNA for such 
proteins or the proteins themselves were used. That was still true even if the mRNA did not 
integrate into the genome. Moreover, the external treatment using dsRNA is not among the closed 
list of exemptions from the regulations. Experts serving the court, including EPA’s expert, also 
agreed “that ‘in vitro’ techniques are key words in the definition of genetically modified organisms 
in the Act” (paragraph 32).  
6. The reasoning used by staff in its March 2018 report was that: “3.11. Regardless of whether the dsRNA 
is created in vitro or in vivo, such molecules are not organisms, as they are unable to be replicated by 
the cell or any other mechanism, and the dsRNA molecules do not cause any permanent6 or heritable 
                                               
Environmental Protection Authority). 
6 Permanent is also a problematic word that neither appears in the HSNO Act nor is defined by staff. Nucleotide 
sequences are also not permanent or there would be no mutations that could arise from changing them. Evolution of 
species would not be possible if nucleotide sequences were permanent. Therefore, permanence cannot be the correct 
test. I presume that staff were looking to distinguish between the stability of a DNA sequence from the changes to 
genetic material that do not rely on the same kind of molecular stability. In which case the question becomes: How 
many generations does a trait have to transmit to be considered heritable? The answer is obvious in genetics, the 
science of inheritance which defines a trait as heritable because it transmits from one to the next generation. Likewise, 
the HSNO Act says “any number of replications”, which includes as few as one. However, the number of generations a 
trait is transmitted could matter to risk assessment. It would depend on the trait, organism and relevant environment. 
Because it could matter to a risk assessment there is a need to subject organisms treated with dsRNA molecules to a 
risk assessment, which would only be done if the techniques were within scope of the HSNO Act. 
Submission on scientific and other matters made to the Decision-Making Committee for reconsideration of APP203395 
Document two of four 4 
change to the treated cell or organism. 3.12. Therefore, we conclude that the treatment of eukaryotic 
organisms with dsRNA does not modify the ‘genes or genetic material’ of the organism by ‘in vitro 
techniques’, and so dsRNA-treated eukaryotic organisms do not meet the definition of a GMO in the 
HSNO Act.”  
7. Firstly, whether or not a molecule is an organism is irrelevant. For example, DNA is not an organism 
but external treatments of organisms with it does create genetically modified organisms. Secondly, the 
DMC itself correctly rejected the staff argument that dsRNA molecules could not replicate in treated 
cells or organisms.7  
8. Finally, each of the conditions used by the staff to disqualify external treatments using dsRNA as 
meeting the definitions of the Act are also wrong. Some molecules of DNA have no known means to 
replicate in some organisms but that does not mean they do not, nor does it mean that self-directed 
replication, as for example that occurs when a bacterium is transformed using a plasmid, is the only 
way through which they may persist and be passed on through genetic material. One alternative 
means is through recombination with or integration into other DNA molecules, as is the case for 
existing genetically modified commercial crop plants. RNA can do the same either via reverse 
transcription and recombination with DNA molecules or recombination with replicating molecules of 
RNA. As I recount in my third submission document, replication and/or recombination of RNA 
molecules can occur in fungi and has occurred to detectable levels between viruses in plants. dsRNA 
molecules do cause permanent6 and heritable changes to genes and other genetic materials. Examples 
                                               
7 See paragraph 4.6 of the DMC decision: “The Committee acknowledged that while siRNA molecules replicate within 
treated eukaryote species (via RNA-dependent RNA polymerase amplification as part of the normal cellular RNA 
interference response)…”. Unfortunately, the DMC instead invoked other equally flawed barriers to heritability. 
Figure 1. A common depiction of genetic engineering and genome editing techniques, adapted to 
show the respective in vitro (highlighted in red) and in vivo stages resulting in modified genes or other 
genetic material. All techniques understood to create genetically modified organisms involve reactions 
resulting in the modification of genes or other genetic material in vivo. dsRNA treatments do the same. 
Modified from https://theconversation.com/organic-farming-with-gene-editing-an-oxymoron-or-a-tool-for-
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include dsRNA-mediated DNA rearrangements and transition mutations. They may also alter traits 
determined by endogenously produced dsRNA-mediated processes in heritable material.8 
9. In addition, the criteria for heritable modification were applied differently for dsRNA treatments than 
they are for other in vitro techniques. Treatments using other mutagens that create genetically 
modified organisms, although some are excluded by the regulations, involve chemicals or molecules 
that do not themselves persist or replicate in treated organism. The criteria used by staff would 
exempt from regulation any number of treatments that are currently regulated.9 
10. For example, it is possible to have dsRNA molecules (and/or treatments contaminated with single-
stranded RNA molecules or denatured dsRNA molecules that are then single-stranded) that are not 
prevented from being translated (Figure 2). Consequently, as the decision is written, organisms that 
are not already genetically modified organisms could be treated with dsRNA molecules that may be 
translated to make ZFN or TALEN proteins. Unmistakably this would be in conflict with the High Court 
ruling in The Sustainability Council of New Zealand Trust v. The Environmental Protection Authority (see 
paragraph 5.3 above) because it would make them genetically modified organisms. Since the DMC 
decision makes no mention of this amongst the excluded conditions, the DMC appears to not have 
recognised that it had formulated a decision that exempts some treatments that are beyond its legal 
authority to exempt. 
11. It is surprising that the DMC used heritability as its sole test rather than also consider whether or not 
the treatment was an in vitro technique (paragraph 4.7 of EPA 2018a). In document one of my 
submission,10 I outlined how the applicant’s and EPA staff’s reference to “synthetic” or “artificially 
synthesised” dsRNA molecules produced using in vitro techniques were not included in the description 
of dsRNA treatments by the former DMC. Retaining these terms would have reinforced that in vitro 
techniques were involved. In addition, in the third document of this submission (first provided to EPA 
on 4 June11), I outlined examples of the in vitro techniques that may be used to both create dsRNA and 
to cause its penetration into cells and organisms where it can modify genes or other genetic material. 
The techniques used to cause penetration are sometimes even the same as used to introduce ZFN and 
TALEN proteins or RNA for the production of those proteins, into cells or organisms. Many are 
described in my fourth submission document.  
12. In addition to how in vitro techniques were defined during this process, other undefined key terms 
were defined in ways that appear to have constructed the DMC’s findings. In Decision paragraph 4.9 
the DMC said that it required evidence of dsRNA integrating into the genome (i.e. according to 
Decision paragraph 4.6, to be chemically attached as part of the DNA polymer of chromosomes in the 
nucleus), or the sequence of nucleotides of a particular dsRNA had to in some other way become 
heritable, for the conclusion to be reevaluated (EPA 2018a). Implicit in the determination text was that 
the modification of genes or other genetic material in treated cells or organisms had to be the 
continued propagation of the dsRNA or a derivative cDNA, rather than the propagation of 
modifications made to genes or other genetic material by the dsRNA. In the third document of my 
submission2 I provide overwhelming evidence of modification of genes or other genetic material that 
can happen following treatment of cells or organisms with dsRNA, different from that outlined by the 
former DMC. 
                                               
8 Heritable material as defined by the HSNO Act. 
9 Namely all those captured by the outcome of The Sustainability Council of New Zealand Trust v. The Environmental 
Protection Authority. 
10 Letter to Dr Stephen Cobb. 
11 Although I now have been made aware that EPA new of this new evidence since at least August 2018. 
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Genetic material 
13. The previous DMC always associated DNA in chromosomes of the nucleus with the phrase “genes or 
other genetic material” in the Decision (see paragraphs 4.5-4.7 of EPA 2018a), and it specifically only 
mentioned alterations of DNA molecules in the chromosomes of a nucleus as necessary evidence for 
reconsideration of its Decision (paragraph 4.9). The DMC therefore wrongly restricted its interpretation 
of “genes or other genetic material” to exclude modifications to the known range of nucleic acids that 
act as genes in eukaryotes (e.g. replicating RNA elements in the cytoplasm of fungi), location of genes 
within cells including the cytoplasm of eukaryotes, and has the effect of equating “genes” with “genetic 
material”. These terms are not synonyms. Neither are they a more cumbersome way of saying, e.g., 
Figure 2. dsRNA treatments that could result in availability of potentially translated RNA 
molecules in vivo. Potential RNA ingredients of exo-dsRNA treatments are shown at the top 
(without implying size of the molecules). All of these are forms of dsRNA molecules which 
are allowed by the 1 May 2018 EPA decision. Some dsRNA molecules (left) may be 
translated directly with or without the classic 5' cap (for eukaryotes) or Shine-Dalgarno 
sequence (for prokaryotes) (Nakagawa et al. 2017; Shatsky et al. 2018). Alternatively, during 
preparation, storage or penetration of living tissue, they may denature (resulting in loss of 
base pairs illustrated by black lines) into ssRNA (right). The ssRNA molecules may be used as 
substrates for translation by ribosomes (bottom). If an RNA molecule also had the reading 
frame for a gene editor, then an exo-dsRNA treatment would result in an outcome already 
regulated. Note that translation of dsRNA molecules is a specifically identified and regulated 
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DNA and RNA.12 Rather, the terms refer to very different things of relevance to the HSNO Act and risk 
assessment and have a long history of use. I encourage the new DMC to correct this mistake. 
14. For the meaning of genes and other genetic material, the DMC used definitions from the Oxford 
English Dictionary. A dictionary of this type supplies definitions that are useful for most broad 
audiences, but are neither technically comprehensive nor fit-for-purpose in this technically demanding 
area of biotechnology. For example, the dictionary definition is useful to say that genes are found in 
chromosomes, but expert molecular biologists do not turn to the dictionary to generate lists of all non-
chromosomal locations of genes, including the genome of mitochondria and chloroplasts or RNA 
elements found in the cytoplasm of fungi. 
15. Reasonable sources for definitions on technical terms of central importance to the May 2018 
determination can include international agreements in the area of biosafety, agriculture and 
conservation. Domestic legislation such as the HSNO Act are written to harmonise New Zealand to 
relevant international agreements and thus share a context for terminology. It is my view that the 
former DMC took upon itself considerable latitude to adopt definitions on terms for which there are 
neither national nor international consensus definitions and overlooked interpretations that could 
conflict with the determination that external treatment using dsRNA does not create a genetically 
modified organism. 
16. In the Convention on Biological Diversity (CBD), Cartagena Protocol on Biosafety (CBD), the 
International Treaty on Plant Genetic Resources for Food and Agriculture (ITPGRFA), among others, the 
definition of genetic material is not articulated as the “DNA of the eukaryotic genome” (language used 
in paragraph 4.6 of EPA 2018a) in the nucleus of eukaryotic cells. Using the definitions from those 
instruments, modification of genetic material can result from changing the DNA of chromosomes in the 
nucleus, but also in other ways, such as by changing the replicating RNA elements in the cytoplasm of 
cells that have these, or modifying the histone proteins of chromosomes in cells that results in 
intergenerational transmission of associated traits. 
16.1. The international community defines genetic resources as a special kind of genetic material, 
one that has actual or potential value. The Convention on Biological Diversity defines genetic 
material as “any material of plant, animal, microbial or other origin containing functional units of 
                                               
12 Parliament chose the words “genes” and “other genetic material”, terminology that predates the HSNO Act and was 
used by the United Kingdom (e.g. COUNCIL DIRECTIVE of 23 April 1990 on the deliberate release into the environment 
of genetically modified organisms (90/220/EEC)), not the words “DNA” and “DNA/RNA”. New Zealand lawmakers had 
two opportunities to say “DNA and RNA” if that is what they wanted to say instead of “genes and other genetic 
material”. The first opportunity would have been in the definition of a genetically modified organisms and the second 
opportunity was in the definition of genetic elements. The wording of genetic elements is newer than the definition of 
genetically modified organisms. It was introduced in the 2002 New Organisms and Other Matters bill. I participated in 
the process through a submission and appearance before the select committee of the day. My submission articulated 
that genetic modification of organisms did not require retention of the modifying nucleic acids and I even used RNA 
interference as one example. (It was already well known by 2002 that external treatments with dsRNA caused 
heritable changes. I reviewed that evidence at the request of then EPA staff in a report I provided in circa 2007.) The 
term genetic element preserved this aspect of heritable modification without defining the molecular causation. The 
existing definition of genetically modified organism was consistent and therefore required no adjustment. Indeed, 
“genetic material” and “heritable material” are operationally synonymous terms in the HSNO Act. 
I acknowledge that in some contexts those speaking about genetic material or heritable material mean genes or DNA. 
It is common in molecular biology to not distinguish between genes, genetic material and heritable material. However, 
these words do have different meanings in context (see footnote 13). For example, the HSNO Act does not define 
heritable material as a synonym of DNA or genes. While there is no definition of genetic material in the HSNO Act, it’s 
used to refer to units of heredity as small as genes to as large as seeds etc, mirroring how the same term is used in UK 
legislation (see above). 
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heredity” (CBD). The ITPGRFA defines both plant genetic resources and plant genetic material as 
“any material of plant origin, including reproductive and vegetative propagating material, 
containing functional units of heredity” (emphasis added to ITPGRFA). Genetic resources are 
described as such things as organisms, seeds, zygotes and cuttings (Europa ; FAO ; Heinemann et 
al. 2018). At the 22nd Session of the Conference of FAO (held in 1983) it was decided that the “‘base 
collection of plant genetic resources’ means a collection of seed stock or vegetative propagating 
material (ranging from tissue cultures to whole plants)…” (emphasis added to UNFAO 1983). 
Therefore, and for some considerable time, genetic material has been a term to mean 
organisms, seeds, zygotes and cuttings, not just DNA in chromosomes found in cell nuclei.13 
Treatments that modify organisms, seeds, zygotes and cuttings using in vitro techniques create 
genetically modified organisms. Failure to embrace this larger meaning of “genes or other genetic 
material” focused the DMC and EPA staff onto too narrow a range of dsRNA treatment effects.  
16.2. The DMC departed from the international convention I discuss above when it said in paragraph 
4.5: “The Committee interpreted this to mean whether any genes or genetic material of a 
eukaryotic cell or organism (including in vitro-cultured cell lines, germline cells of whole animals or 
plants, etc.) would be modified by the treatment with externally applied double-stranded RNA 
molecules” (emphasis in bold added). Herein it unmistakably fails to equate genetic material with 
the cultured cell lines, germline cells or whole animals or plants and instead as something less than 
these things and not obviously different from genes themselves. Notably, as discussed in paragraph 
16.4, genetic material may be modified by inclusion of genetic elements. 
16.3. Neither these international instruments nor domestic law define the term “modify.” The term 
“modify” as used by international agencies such as the UN Food and Agriculture Organisation 
includes the “chemical modifications of DNA and chromatin, for instance, affecting the degree of 
chromatin compaction or the accessibility of regulatory sequences to transcription factors” which 
may be “meiotically and mitotically inherited” (emphasis added to CGRFA 2015), not just changes 
in sequences of nucleotides in DNA molecules in chromosomes found in nuclei, or covalent linkage 
between DNA and RNA molecules. As discussed in the third document of my submission, 
modifications of the kind described by UN FAO can result from an external treatment with dsRNAs. 
Moreover, dsRNA can cause heritable effects, such as through transition mutations and DNA 
rearrangements, without needing to propagate along with the modifications that it makes. Treating 
cells with dsRNA resulting in RNA-dependent DNA methylation, one RNA interference pathway, is a 
                                               
13 (A) “Referring to genetic material as ‘any material of plant origin, including reproductive and vegetative propagating 
material, containing functional units of heredity’ has a long tradition in management of GRFA [genetic resources for 
food and agriculture], and is consistent with classical applied genetics because the predominant tool is breeding. The 
agricultural genetics literature from the 1940s explicitly equated ‘genetic material’ with that which could recreate the 
plant (seeds or propagules) (Weiss, 1943)” (Heinemann et al. 2018). (B) “(a) ‘plant genetic resources’ means the 
reproductive or vegetative propagating material of the following categories of plants: • (i) cultivated varieties 
(cultivars) in current use and newly developed varieties; (ii) obsolete cultivars; (iii) primitive cultivars (land races); (iv) 
wild and weed species, near relatives of cultivated varieties; (v) special genetic stocks (including elite and current 
breeders' lines and mutants);” (UNFAO 1983). (C) “Genetic resources (GRs) refer to genetic material of actual or 
potential value. Genetic material is any material of plant, animal, microbial or other origin containing functional units 
of heredity. Examples include material of plant, animal, or microbial origin, such as medicinal plants, agricultural crops 
and animal breeds.” Source: World Intellectual Property Organization (WIPO) https://www.wipo.int/tk/en/genetic/. (D) 
“…plant genetic material is to be understood as any plant material containing genetic information which is capable of 
self-reproduction or of being reproduced in a biological system” (Leskien and Flitner 1997). Note that quote (D) makes 
explicit that genetic material has the qualities of both heritable material (capable of self-replication) and genes (being 
reproduced in a biological system) as defined in the HSNO Act. 
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mutagenesis technique not excluded by the regulations. 
16.4. The HSNO Act does not restrict its scope of in vitro techniques or heritable changes to those 
that alter nucleotide order in molecules of DNA. If it did, there would be no need for the definition 
of a genetic element. Genetic elements are defined as – 
(a) “heritable material; and 
(b) any genes, nucleic acids, or other molecules from the organism that can, without human 
intervention, replicate in a biological system and transfer a character or trait to another 
organism or to subsequent generations of the organism.” 
Heritable material means “viable biological material, including gametes and spores, arising from 
the organism that can, without human intervention, regenerate the organism or reproduce a new 
generation of the same species of the organism.” Genetic elements are both things such as seeds 
and things such as nucleic acids. The HSNO Act recognises that genetic elements are a source of 
risk and therefore must be taken into account. It would be incongruous to exclude genetic 
elements created through the use of in vitro technologies from what is considered to be a 
regulated item under the HSNO Act. 
16.5. As set out in my third submission document, methylation patterns established by external 
dsRNA treatments replicate without human intervention and transfer a trait to subsequent 
generations. Silencing mediated by persistent rounds of siRNA generation is also transmitted and 
does not require human intervention to do so. Heritability of traits, by whatever means, due to 
modifications using in vitro techniques is a special feature of the risks to be regulated and why 
genetically modified organisms are included as new organisms in the HSNO Act. 
Precaution with consultation 
17. I encourage the new DMC to review its consultation practices. It may be worthwhile to also consult the 
Defence Technology Agency. The new DMC also should more thoroughly support the government 
agencies with which it already consults. Each of these agencies should receive the EPA’s staff report well 
in advance of a decision by the DMC, providing time for them to consult with their own staff and chief 
scientists. 
17.1. The 2018 determination followed invitations to the Ministry of Primary Industries and the 
Department of Conservation to comment on the use of externally applied dsRNA. The former 
never responded; the latter was not aware of any biosecurity risks.  
17.2. In the matter of DOC, EPA had a responsibility to have evaluated risks to biosecurity to inform 
that agency rather than just determine that the use of dsRNA was out of scope of legislation. If it 
had, it might have realised that the decision could result in the release of whole or partial viruses. 
In the matter of MPI’s unresponsiveness, I believe that the EPA should have confirmed that MPI did 
not wish to reply, felt competent to reply and had adequate time to reply. If MPI felt that it did not 
have access to the necessary expert advice, it is reasonable to expect that EPA would work with 
MPI to find it. 
18. The short timeline and aborted and limited consultation undertaken by EPA in 2018 was also out of step 
with international practice. In other countries, a decision by regulators of this magnitude has involved 
convening expert scientific advice, public comment and review by government. 
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18.1. The white paper produced following a meeting of the Scientific Advisory Panel (SAP) of the US 
Federal Insecticide, Fungicide, Rodenticide Act and the United States Environmental Protection 
Agency concluded that the technology deserves risk assessment. The US Environmental Protection 
Agency “consulted with the SAP on scientific issues that might be unique to RNAi and how they 
could fit under the existing risk assessment framework.” The SAP agreed with the US EPA 
“regarding inadequacies of the current environmental fate and non-target effects testing 
frameworks for dsRNA PIPs [plant incorporated protectants] and exogenously applied dsRNA 
products. Uncertainties in the potential modes of action in non-target species, potential for 
chronic and sublethal effects, and potential unintended consequences in the various life stages 
of non-target organisms are sufficient justification to question whether the current Agency 
framework for ecological effects testing is applicable to dsRNA PIPs” (emphasis added to FIFRA 
2014). 
18.2. Presently in Australia there is before Parliament a proposal to change the definition of a 
genetically modified organism (OGTR 2018). These reconsiderations also included external 
treatments of organisms with dsRNA. Rather than attempt to deregulate dsRNA techniques with a 
three-person committee that acted on a short internal report, Australia conducted a 
comprehensive process that included multiple agencies (i.e. Office of the Gene Technology 
Regulator, Food Standards Australia New Zealand, Legislative and Governance Forum on Gene 
Technology, Department of Health) involving extensive public consultations, followed by a 
parliamentary process that serves as a final review because the proposed deregulation still could 
be disallowed. While some kinds of treatments with dsRNA may become excluded from Australia’s 
regulations, allowed treatments would be far more limited than would be allowed under the 1 May 
2018 decision by EPA. 
18.3. In this submission I will not evaluate the scientific validity of the arguments for allowing certain 
treatments in Australia.14 And in any case, the recommendations may never be implemented. I will, 
however, explain how less expansive the Australian proposal is compared to the New Zealand 
decision. I would also point out that by including external treatments of organisms with dsRNA in a 
proposal to discuss their exemption from regulations, they had not arrived at the conclusion that 
treatments do not create genetically modified organisms under still current (as of this writing) 
regulations. 
18.4. The regulatory amendment specifically constrains the dsRNA molecules used in any kind of 
treatment in the following ways. “This item provides that techniques involving applying RNA to an 
organism to temporarily induce RNA interference are not gene technology, provided that: 
• the RNA cannot be translated into a polypeptide 
• the organism’s genome sequence cannot be altered as a result, and 
• an infectious agent cannot be produced.”15 
As demonstrated in my third submission document, to meet these conditions would require testing 
and forethought that is well beyond the requirements set by the New Zealand EPA decision. For 
example: 
                                               
14 I do not know whether the Australian Office of the Gene Technology Regulator was aware, for example, of 
replicating RNA molecules in the genomes of some organisms, the effects of dsRNA on prokaryotes, or the longevity of 
heritable effects including by means of replication separate from methylation. Moreover, Australia has different 
international obligations to New Zealand. Notably, it has not ratified the Cartagena Protocol on Biosafety. 
15 EXPLANATORY STATEMENT Select Legislative Instrument 2019 No. XX Gene Technology Act 2000 
https://www.legislation.gov.au/Details/F2019L00573/Download on 15 July 2019.  
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18.4.1. the dsRNA would have to be limited in size and sequence characteristics to ensure no 
peptides could be produced in any exposed species (Figure 2). 
18.4.2. the in vitro techniques used to isolate, amplify and purify the dsRNA would have to be of a 
quality that ensured that no viral genomes in whole or in part were contaminating the 
intended dsRNA formulation. 
18.4.3. the species or cells treated would have to be limited to those that did not have RNA-
dependent DNA polymerase activity. 
18.5. None of the above qualifications, indeed no qualifications of any kind on the dsRNA, was placed 
on the kinds of treatments allowed by EPA in its May 2018 decision, which is remarkable both in 
absolute terms and in comparison with other jurisdictions. Open air treatments, as forecast by the 
EPA (EPA 2018b), would cause simultaneous multispecies exposures including potential human 
exposures. There is so little knowledge of the potential effects. Only in the last couple of months 
has it even been reported that human skin cells react to external dsRNA exposure (Liao et al. 
2019).16 
18.6. The 1 May 2018 decision as far as I can tell propelled New Zealand further than possibly all 
other countries in the world in its breath and underestimation of this new technology and its 
anticipated powerful effects on the organisms intended, and not intended, to be exposed to it. 
Even in countries that have far more experience with the release and management of genetically 
modified organisms, such as Australia and the United States, there is no equivalent of the New 
Zealand EPA decision on external treatments of organisms with dsRNA. 
In a nutshell. 
19. The use of dsRNA as an external treatment of cells or organisms is an in vitro technique as understood 
in the context of the HSNO Act4. Similar to other regulated in vitro treatments, such as the use of gene 
editing nucleases, dsRNA treatments modify genes or other genetic material causing heritable effects 
with sometimes the dsRNA or a derivative homologous nucleic acid not persisting in the treated cell or 
organism. Cells or organisms that have been treated with dsRNA “have been modified by in vitro 
techniques” and if they reproduce then their descendants have genes or other genetic material 
“inherited or otherwise derived, through any number of replications, from any genes or other genetic 
material which has been modified by in vitro techniques”. Therefore, both clauses (a) and (b) of the 
HSNO Act definition of a genetically modified organism are satisfied even though satisfying either of 
them would be sufficient to conclude that external treatments of cells or organisms with dsRNA creates 
genetically modified organisms. 
The process used to decide the contrary was extraordinary by international standards. It was unbefitting 
the seriousness of the decision as demonstrated by the investigative and consultative processes being 
used in Australia, Europe and the United States. Moreover, the historical, legislative and international 
treaty context of the words adopted by the HSNO Act did not figure in the EPA’s interpretations. Terms 
such as “genetic material”, “heritable material” and “genetic element” are used in a variety of ways in 
different contexts as well as having informal, jargon or formal meanings. Therefore, in some contexts 
these terms are synonyms and in others they mean very different things. There was no apparent 
attempt in either the staff report or the DMC report to place these terms into context of the purpose 
and principles of the new organisms provisions of the HSNO Act. Doing so reveals an underlying logic 
                                               
16 “[T]he authors treated early-passaged volar keratinocytes with polyinosinic:polycytidylic acid (poly[I:C]) (a synthetic 
analogue of dsRNA), and they found that poly(I:C) suppresses KRT9 expression.” 
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and cohesion of word choice, making apparent the risk special to gene technologies and the potential 
dispersal pathways of modified organisms and genes. Case-by-case risk assessments, of external dsRNA 
treatments of cells or organisms, performed by the EPA is justified and appropriate in the context of 
New Zealand society’s precautionary approach to gene biotechnology. To accomplish this, the 1 May 






Prof Jack A Heinemann17 
16 September 2019 
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